Your browser is no longer supported. Please, upgrade your browser.
XNCR Xencor, Inc. daily Stock Chart
Xencor, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own0.20% Shs Outstand57.06M Perf Week-4.11%
Market Cap2.29B Forward P/E- EPS next Y-1.74 Insider Trans0.00% Shs Float56.08M Perf Month-6.83%
Income-80.20M PEG- EPS next Q-0.23 Inst Own94.62% Short Float6.85% Perf Quarter17.33%
Sales70.80M P/S32.34 EPS this Y135.20% Inst Trans0.59% Short Ratio12.26 Perf Half Y40.39%
Book/sh10.00 P/B4.01 EPS next Y-10.10% ROA-12.00% Target Price45.64 Perf Year14.25%
Cash/sh10.26 P/C3.91 EPS next 5Y- ROE-13.60% 52W Range19.35 - 43.90 Perf YTD16.55%
Dividend- P/FCF- EPS past 5Y23.50% ROI2.30% 52W High-8.70% Beta0.93
Dividend %- Quick Ratio9.10 Sales past 5Y75.10% Gross Margin- 52W Low107.13% ATR1.60
Employees166 Current Ratio9.10 Sales Q/Q-32.80% Oper. Margin- RSI (14)52.44 Volatility3.04% 4.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-115.90% Profit Margin- Rel Volume0.56 Prev Close40.90
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume313.37K Price40.08
Recom1.80 SMA201.16% SMA507.40% SMA20020.37% Volume174,497 Change-2.00%
Mar-04-20Initiated Barclays Underweight $28
Feb-25-20Upgrade Guggenheim Neutral → Buy $43
Jan-30-20Initiated RBC Capital Mkts Outperform $44
Nov-20-19Resumed Guggenheim Neutral
Aug-07-19Downgrade Raymond James Outperform → Mkt Perform
Aug-07-19Downgrade Guggenheim Buy → Neutral
Jun-13-19Initiated Mizuho Buy
Apr-12-19Initiated Guggenheim Buy
Mar-27-19Initiated Berenberg Buy $45
Mar-15-19Initiated Raymond James Outperform
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Jul-11-14Initiated Oppenheimer Outperform $22
Oct-14-20 05:00PM  
Oct-13-20 12:03PM  
Oct-02-20 09:00AM  
Sep-23-20 12:09PM  
Sep-09-20 04:01PM  
Sep-03-20 08:01AM  
Aug-05-20 04:01PM  
Aug-04-20 05:25PM  
Jul-31-20 10:49PM  
Jul-28-20 05:01PM  
Jul-14-20 11:14AM  
Jul-08-20 08:01AM  
Jun-30-20 11:35PM  
Jun-22-20 09:06AM  
Jun-08-20 01:48PM  
May-26-20 04:01PM  
May-15-20 12:01AM  
May-13-20 05:00PM  
May-11-20 01:35PM  
May-08-20 09:30PM  
May-07-20 04:01PM  
Apr-30-20 04:01PM  
Apr-13-20 03:49PM  
Apr-07-20 02:10PM  
Mar-26-20 08:23AM  
Mar-25-20 04:01PM  
Mar-02-20 02:55PM  
Feb-28-20 07:43AM  
Feb-26-20 11:59AM  
Feb-24-20 05:45PM  
Feb-18-20 08:01AM  
Feb-17-20 12:30PM  
Feb-06-20 04:01PM  
Feb-05-20 10:28AM  
Jan-09-20 05:10PM  
Jan-08-20 12:08PM  
Dec-30-19 10:13AM  
Dec-20-19 08:01AM  
Dec-18-19 08:01AM  
Dec-14-19 08:05PM  
Dec-09-19 10:00AM  
Nov-19-19 12:58PM  
Nov-18-19 11:48PM  
Nov-13-19 04:01PM  
Nov-06-19 09:00AM  
Nov-05-19 06:05PM  
Oct-29-19 04:01PM  
Oct-28-19 10:31AM  
Oct-21-19 12:55PM  
Oct-10-19 03:34PM  
Sep-26-19 04:01PM  
Sep-10-19 04:01PM  
Aug-23-19 10:00AM  
Aug-22-19 09:15PM  
Aug-21-19 06:53AM  
Aug-08-19 11:13AM  
Aug-06-19 06:05PM  
Aug-01-19 04:01PM  
Jul-30-19 04:01PM  
Jul-12-19 06:16PM  
Jul-09-19 12:52PM  
Jul-02-19 08:58AM  
Jun-27-19 08:01AM  
Jun-26-19 10:12AM  
Jun-24-19 06:00PM  
Jun-08-19 09:14AM  
Jun-03-19 08:01AM  
May-23-19 08:01AM  
May-10-19 09:23AM  
May-09-19 04:43PM  
May-08-19 04:01PM  
May-06-19 08:01AM  
May-02-19 04:01PM  
May-01-19 01:22PM  
Apr-30-19 08:01AM  
Apr-29-19 09:55PM  
Apr-02-19 08:01AM  
Apr-01-19 04:05PM  
Mar-08-19 08:01AM  
Mar-06-19 07:00AM  
Mar-01-19 12:30PM  
Feb-28-19 09:15AM  
Feb-26-19 09:48PM  
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kuch John JSr. Vice President & CFOJun 12Option Exercise11.0510,000110,50090,602Jun 16 08:45 PM
STAFFORD JOHN S III10% OwnerApr 06Sale27.43644,77117,685,509606,005Apr 08 04:26 PM
Ronin Capital, LLC10% OwnerMar 20Sale29.8950,7701,517,6425,012,430Mar 23 05:37 PM
Ronin Capital, LLC10% OwnerMar 19Sale28.2326,800756,5935,063,200Mar 23 05:37 PM
STAFFORD JOHN S III10% OwnerJan 08Sale36.6860,8762,232,9321,250,776Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 07Sale35.956,047217,3901,311,652Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerJan 06Sale35.8158,8622,107,9071,317,699Jan 08 05:28 PM
STAFFORD JOHN S III10% OwnerDec 26Sale40.044,119164,9251,376,561Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 24Sale39.7143,7201,736,1211,380,680Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 23Sale39.5191,6773,622,3421,424,400Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 20Sale39.3973,4232,892,1321,516,077Dec 26 05:07 PM
STAFFORD JOHN S III10% OwnerDec 11Sale38.6837,9511,467,9451,589,500Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 10Sale40.13252,22510,121,7891,627,451Dec 11 06:48 PM
STAFFORD JOHN S III10% OwnerDec 09Sale41.64120,3245,009,7501,879,676Dec 11 06:48 PM